A Phase 2 clinical study of AB-1005 (AAV2-GDNF), an experimental gene therapy AskBio is developing for Parkinson’s disease, is recruiting patients who are experiencing motor fluctuations despite being on a stable medication regimen for at least a month. Called REGENERATE-PD (NCT06285643), the study aims to enroll 87…
The U.S. Food and Drug Administration (FDA) has rejected for the second time AbbVie’s application of ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in adults with advanced Parkinson’s disease. In a complete response letter to AbbVie, the FDA said the decision is based on observations from an inspection…
NeuroOne Medical Technologies said the Centers for Medicare and Medicaid Services (CMS) granted a new ICD-10-PCS code to its OneRF Ablation procedure, a development the company said will lead to greater use of the technology. Effective Oct. 1, hospitals will be allowed to report inpatient procedures performed with…
Coya Therapeutics is building upon its collaboration with the Houston Methodist Research Institute, in Texas, to advance research into exosomes, or tiny packets released from regulatory T-cells (Tregs), a type of immune cells that keep inflammation in check. These exosomes contain molecules that, similar to Tregs, can cross the…
Researchers at University College London (UCL) have developed a test that accurately identified Parkinson’s disease up to seven years before its symptoms manifested by measuring levels of eight biomarkers in the blood, a study reports. “We set out to use state-of-the-art technology to find new and better biomarkers for…
A magnetic resonance imaging (MRI)-guided approach known as the ClearPoint Navigation System is being used in a Phase 1/2a clinical trial to enable the precise surgical delivery of ANPD001, an investigational stem cell therapy for Parkinson’s disease, its developer, Aspen Neuroscience, announced. The open-label ASPIRO trial…
Remote health monitoring company Empatica is partnering with the consortium Mobilise-D to advance the use of digital endpoints in clinical care and research across disorders that include Parkinson’s disease. The collaboration will integrate Mobilise-D’s validated digital mobility outcomes (DMOs) with Empatica’s Health Monitoring Platform. With this,…
Researchers at the University of Birmingham have shown that reducing dopamine signaling in the brain can impair people’s ability to recognize emotions or understand others’ mental states (mentalizing), symptoms that may be experienced by those with Parkinson’s disease. The study, “Disruption of dopamine D2/D3 system function impairs the…
Merck, in collaboration with the Michael J. Fox Foundation for Parkinson’s Research (MJFF), is providing a service to the scientific community to detect low levels of phospho-serine [pS65]-Ub, a biomarker associated with nerve cell dysfunction in people with Parkinson’s disease. The SMCxPRO platform is an ultrasensitive…
Patient enrollment is now complete in a Phase 2 trial that’s assessing the safety and efficacy of oral risvodetinib, being developed by Inhibikase Therapeutics to slow or stop the progression of Parkinson’s disease. The 201 trial (NCT05424276) has enrolled 120 participants across 32 sites in the U.S.,…
Get regular updates to your inbox.
